Pro-GA, as a cell membrane permeable GGCT inhibitor, might become a promising novel therapeutic agent against various cancers expressing high levels of GGCT such as breast, ovarian, cervical, lung, urinary bladder, colon cancers, osteosarcoma, esophageal squamous cell carcinoma, and glioma. This evidence concerns the gene GGCT and colonic neoplasm.